Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities (2016 - 2026)

Ocular Therapeutix has reported Cash from Financing Activities over the past 14 years, most recently at $294000.0 for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 92.97% year-over-year to $294000.0; the TTM value through Mar 2026 reached $557.8 million, up 3601.61%, while the annual FY2025 figure was $561.7 million, 69.14% up from the prior year.
  • Cash from Financing Activities for Q1 2026 was $294000.0 at Ocular Therapeutix, down from $449.4 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $449.4 million in Q4 2025 and troughed at $78000.0 in Q1 2023.
  • A 5-year average of $62.7 million and a median of $4.2 million in 2025 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: soared 411724.36% in 2024 and later plummeted 98.7% in 2025.
  • Year by year, Cash from Financing Activities stood at $458000.0 in 2022, then soared by 23517.9% to $108.2 million in 2023, then tumbled by 95.83% to $4.5 million in 2024, then surged by 9857.37% to $449.4 million in 2025, then plummeted by 99.93% to $294000.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for OCUL at $294000.0 in Q1 2026, $449.4 million in Q4 2025, and $10.4 million in Q3 2025.